Serono drug draws FDA warning on heart risk
The FDA issued a warning that Serono's multiple sclerosis drug Novantrone raised the risk of heart damage. A boxed warning has been added to the drug's packaging, and the Swiss company has advised patients to be tested for heart disease before dosing. Patients taking Novantrone can experience congestive heart failure during therapy or even years after therapy is completed. The drug was approved by the FDA in 2000. In recent months the agency has raised a number of drug alerts as it responds to criticism that it ignored earlier signs of unsafe drugs.
- read this story from Dow Jones for more on the warning
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
